The Issues of the Authorization for Emergency Use of Vaccines and Relief for Victims of Vaccination

ABSTRACT

COVID-19 ravaged the world, and due to the special circumstances of emergency preventive needs, the vaccine was approved to be marketed under the emergency use authorization without completing clinical trials. Since the unknown and potential risks borne by the vaccinees are higher, the injuries caused by the vaccination are compensated by the relief system. As to the manufacture or importation of the vaccination under special approval, the central authority could have made its own review and decision to approve it or reject. However, the actual decision is given to the expert review meeting giving advisories. And the situation in respect of the review of injury compensation of the preventive vaccination is similar with it. The competent authority is suspected of controlling the results of the evaluation by the selection of expert members and relieving itself of responsibility. If a civil servant of the competent authority or an outside expert selected by it during the examination process of the vaccine approved for the national use commits any illegal misconduct of breaches of professionalism and causes injury to the vaccine recipient, a national compensation to the both sides could be filed at the same time. Nevertheless, all of the accused should be restricted that he couldn't claim a right for compensation to a third party in respect of the same issue of injury. Additionally, all vaccines, no matter they are manufactured domestically or imported under special approval, should be included in the scope of the vaccine victimization remedies, and the EUA program should be considered leniently, and the unknown and potential risks of the insufficient medical evidence shouldn't be borne by the vaccine recipients.